March 19, 2012
Lyndsay Harris, MD, has been appointed Co-Leader of the Case Comprehensive Cancer Center Breast Cancer Research Program in Development and Medical Director of the Breast Cancer Program at University Hospitals (UH) Case Medical Center Seidman Cancer Center. She is proposed for primary appointment as Professor of Medicine in the Division of Hematology and Oncology at UH Case Medical Center and Case Western Reserve University School of Medicine.
Dr. Harris is an internationally recognized authority on breast cancer treatment and research. In her new role, she will expand the clinical research base in breast cancer, including identification and use of genomic and other biomarkers of high-risk disease and the expansion of studies in breast cancer metastasis.
Dr. Harris has published more than 90 scientific research articles, chapters and reviews, with a focus on breast cancer treatment. In addition to conducting clinical trials of new agents and novel approaches for patients with metastatic disease, she has made important contributions to the understanding of the molecular subtypes of breast cancer and the implication of gene, gene expression, and protein expression profiles on treatment response and resistance. She is a leader in the field of “personalized medicine.” She has also led national initiatives to define the optimal role of serum tumor markers in breast cancer management and served as first author of the ASCO published recommendations.
Dr. Harris holds a variety of national and international committee leadership roles for the following organizations: American Society of Clinical Oncology (ASCO), Cancer and Leukemia B (CALGB), Eastern Cooperative Oncology Group (ECOG), Pan American Cancer Trials Network, (Neo) ALTTO International Adjuvant Breast Cancer Clinical Trial and the Novartis. Dr. Harris has also served on scientific review committees for the U.S. Department of Defense, Komen Breast Cancer Foundation, National Cancer Institute and ASCO. She is an invited reviewer for many of the top journals in oncology, and serves as an editor for BMC Genomics and Breast Cancer Research and Treatment.
Dr. Harris earned an MD in 1988 from the University of Alberta, Edmonton, Canada. She completed specialty training in internal medicine at the University of Alberta and subspecialty fellowship in Medical Oncology at the University of British Columbia (Vancouver Cancer Agency) in 1993. She subsequently relocated to the United States, and pursued additional subspecialty training in breast cancer at Georgetown University.
In 1994, Dr. Harris joined the faculty of Georgetown where she served as Instructor until 1996. She subsequently became Assistant Professor of Medicine at Duke University until 1999 when she was recruited to the Dana Farber Cancer Institute and Harvard Medical School.
At Harvard, Dr. Harris was the Deputy Director for Translational Research, Breast Oncology Program, Dana-Farber Cancer Institute. She was then recruited as Associate Professor of Medicine to Yale University in 2005. At Yale, Dr. Harris held a variety of leadership positions, including Director of the Breast Cancer Disease Unit, Head of Breast Medical Oncology, Co-Leader of the Cancer Genetic and Genomics Program, and Director of the Yale Cancer Center Clinical Trials Support Core. Dr. Harris holds board certifications from the American Board of Internal Medicine in Internal Medicine and Medical Oncology.